

ABERDEEN, Scotland and Singapore, 16th November 2016 – Following presentation of top-line results from its TRx-237-015 Phase 3 clinical trial in Alzheimer’s disease at the 2016 Alzheimer’s Association International Conference (AAIC) in Toronto, Canada in July, TauRx today confirms publication of the full study results in [*The Lancet*](#).¹

In this publication, the study authors describe the efficacy and safety of the first tau-aggregation inhibitor therapy in this population with mild or moderate Alzheimer’s disease.

While overall the study failed to meet its co-primary endpoints, the authors discuss the findings from this and the previous Phase 2 study² which suggest LMTX[®] monotherapy might be beneficial in patients with mild to moderate Alzheimer’s disease. In a review of the study publication also published in [*The Lancet*](#)³, Michael S. Rafii, Alzheimer’s Therapeutic Research Institute, University of Southern California, comments on the work of study authors Gauthier and colleagues, and discusses how tau PET imaging may better explain the diagnosis pathway. He adds that this study represents a valuable step in the field and that optimism around the potential to halt or even prevent Alzheimer’s disease is growing.

Initial results from the second of the two TauRx Alzheimer’s disease Phase 3 trials (study TRx-237-005) confirm the monotherapy findings discussed in *The Lancet* publication and will be presented at the 9th Clinical Trials on Alzheimer’s Disease (CTAD) conference in December 2016. It is TauRx’s intention to publish the results of this second study shortly.

For further information on *The Lancet* publication of study TRx-237-015 visit <http://taurx.com/recent/>.

-Ends-

About Study TRx-237-015 and the LMTX[®] Phase 3 Trials

Study TRx-237-015, was a randomised double-blind placebo-controlled study in 891 subjects with mild or moderate Alzheimer's disease that compared LMTX[®] and control for 15 months. The safety profile of LMTX[®] in the study was acceptable, with rates of amyloid-related imaging abnormalities reported similar to placebo arms in recent Phase 3 trials, and with the overall adverse event profile also similar to those typically seen in Phase 3 studies of novel late-stage Alzheimer's disease treatments. The most common adverse events occurred in the gastrointestinal and urinary tracts, and were typically mild in nature and easily controlled. The trial is part of the Phase 3 programme of LMTX[®] in Alzheimer's disease and behavioural variant frontotemporal dementia.

About Alzheimer's disease

Alzheimer's disease (AD) is a progressive neurologic disease of the brain that causes damage to neurons - the specialized cells of the nervous system that enable the flow of information, thoughts and memories in the brain. When Alzheimer's damages neurons it leads to loss of memory and reasoning, which can affect a person's ability to interact socially or function at work. No treatment yet exists to halt the progression of Alzheimer's-related dementia, delay its onset, or prevent it from occurring. Currently available drugs only temporarily treat the symptoms.⁴

About tau aggregation inhibitors

TauRx's tau aggregation inhibitors (TAIs) have arisen from nearly 30 years of research. TAIs work by undoing the tau tangles that cause dementia, thereby slowing and even arresting memory loss.⁵ LMTX[®] is a stable reduced form of methylthioninium. The first-generation TAI, rember[®] was a patented, highly-purified version of methylene blue, a compound previously used to treat a variety of conditions.

About TauRx Therapeutics Ltd

TauRx Therapeutics Ltd is a member of the TauRx Pharmaceuticals group which is developing technology spun-out from the University of Aberdeen, Scotland, and was established in Singapore in 2002 with the aim of developing new treatments and diagnostics for a range of neurodegenerative diseases. The company's tau aggregation inhibitor, LMTX[®], targets aggregates of abnormal fibres of tau protein that form inside nerve cells in the brain, giving rise to 'tau tangles'. TauRx's headquarters are in Singapore and its primary research facilities are based in Aberdeen. For more information, please visit: <http://www.taurx.com>.

TauRx Pharmaceuticals Ltd. 3, Shenton Way, #21-04, Shenton House, Singapore 068805, Republic of Singapore

TauRx Therapeutics Ltd. 3, Shenton Way, #21-04, Shenton House, Singapore 068805, Republic of Singapore

TauRx Research Facility Liberty Building, Foresterhill Road, Aberdeen AB25 2ZP, UK

For further information visit www.taurx.com

References

1. Gauthier S, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomized, controlled, double-blind, parallel-arm, phase 3 trial. *The Lancet* 2016. Available at: [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(16\)31275-2/fulltext](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31275-2/fulltext) Accessed 16 November 2016
2. Wischik CM, Staff RT, Wischik DJ, et al. Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease. *J Alzheimer's Dis* 2015; 4:705.20
3. Rafii M. Targeting tau protein in Alzheimer's disease. *The Lancet* 2016. Available at: [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(16\)32107-9/abstract](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32107-9/abstract) Accessed 16 November 2016
4. Alzheimer's Association. 2015 Alzheimer's disease facts and figures. Available at: http://www.alz.org/facts/downloads/facts_figures_2015.pdf Accessed 2 February 2016.
5. Wischik CM, et al. Tau-aggregation inhibitor therapy for Alzheimer's disease. *Biochem Pharmacol* 2014;88:529-39

Media Contacts

Email: taurxpress@hkstrategies.com

Website: <http://www.taurx.com>